These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22196123)

  • 1. Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors.
    Park H; Jeong Y; Hong S
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1027-30. PubMed ID: 22196123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel BRAF kinase inhibitors with structure-based virtual screening.
    Park H; Choi H; Hong S; Hong S
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5753-6. PubMed ID: 21873050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.
    Park H; Lee S; Hong S
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3784-7. PubMed ID: 26259807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based virtual screening approach to the discovery of p38 MAP kinase inhibitors.
    Choi H; Park HJ; Shin JC; Ko HS; Lee JK; Lee S; Park H; Hong S
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2195-9. PubMed ID: 22342625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.
    Holladay MW; Campbell BT; Rowbottom MW; Chao Q; Sprankle KG; Lai AG; Abraham S; Setti E; Faraoni R; Tran L; Armstrong RC; Gunawardane RN; Gardner MF; Cramer MD; Gitnick D; Ator MA; Dorsey BD; Ruggeri BR; Williams M; Bhagwat SS; James J
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5342-6. PubMed ID: 21807507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.
    Wenglowsky S; Ahrendt KA; Buckmelter AJ; Feng B; Gloor SL; Gradl S; Grina J; Hansen JD; Laird ER; Lunghofer P; Mathieu S; Moreno D; Newhouse B; Ren L; Risom T; Rudolph J; Seo J; Sturgis HL; Voegtli WC; Wen Z
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5533-7. PubMed ID: 21802293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based de novo design of Eya2 phosphatase inhibitors.
    Park H; Ryu SE; Kim SJ
    J Mol Graph Model; 2012 Sep; 38():382-8. PubMed ID: 23085179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based De Novo Design for the Discovery of Miniprotein Inhibitors Targeting Oncogenic Mutant BRAF.
    Ham JM; Kim M; Kim T; Ryu SE; Park H
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.
    Park H; Bahn YJ; Ryu SE
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4330-4. PubMed ID: 19497739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
    Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
    Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors.
    Li QS; Li CY; Lu X; Zhang H; Zhu HL
    Eur J Med Chem; 2012 Apr; 50():288-95. PubMed ID: 22361686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
    Gopalsamy A; Ciszewski G; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 May; 19(10):2735-8. PubMed ID: 19362830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
    Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds.
    Caballero J; Alzate-Morales JH; Vergara-Jaque A
    J Chem Inf Model; 2011 Nov; 51(11):2920-31. PubMed ID: 22011048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of MEK/PI3K dual inhibitor via structure-based virtual screening.
    Park H; Lee S; Hong S
    Bioorg Med Chem Lett; 2012 Aug; 22(15):4946-50. PubMed ID: 22771009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors.
    Li CY; Li QS; Yan L; Sun XG; Wei R; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Jun; 20(12):3746-55. PubMed ID: 22583669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-Raf kinase inhibitors: hit enrichment through scaffold hopping.
    Gopalsamy A; Shi M; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2431-4. PubMed ID: 20307980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
    Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based virtual screening approach to the discovery of novel PTPMT1 phosphatase inhibitors.
    Park H; Kim SY; Kyung A; Yoon TS; Ryu SE; Jeong DG
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1271-5. PubMed ID: 22115589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.